|
Plerixafor Clinical Trials
5 actively recruiting trials across 5 locations
▲ +1 trial since August 2026
Also known as: AMD 3100, AMD-3100, AMD3100, JM-3100, LM-3100 +3 more
Pipeline
Phase 2: 3Phase 1/2: 2
Top Sponsors
- National Cancer Institute (NCI)2
- Washington University School of Medicine1
- Thomas Jefferson University1
- M.D. Anderson Cancer Center1
Indications
- Cancer5
- Multiple Myeloma2
- Pre-transplant Purging1
- Post-transplant MRD-guided Maintenance Therapy1
- Acute Myeloid Leukemia, Pediatric1
Bethesda, Maryland1 trial
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
National Institutes of Health Clinical Center
Phase 1/2
St Louis, Missouri1 trial
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine
Phase 1/2
Buffalo, New York1 trial
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Roswell Park Cancer Institute
Phase 2
Philadelphia, Pennsylvania1 trial
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University Hospital
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.